Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Abdominal Cancer
100%
Colorectal Carcinoma
75%
Esophageal Cancer
63%
Overall Survival
54%
Esophagectomy
51%
Chemotherapy
44%
Neoplasm
44%
Adjuvant Chemotherapy
40%
Recurrent Disease
40%
Gastrectomy
40%
Oxaliplatin
38%
Malignant Neoplasm
37%
Non Small Cell Lung Cancer
36%
Programmed Cell Death
35%
Metastatic Colorectal Cancer
34%
Rectum Cancer
34%
Adenocarcinoma
31%
Colon Carcinoma
31%
Esophageal Squamous Cell Carcinoma
28%
Chemoradiotherapy
28%
Liver Metastasis
28%
Tumor
28%
Postoperative Complication
27%
Lung Adenocarcinoma
25%
Programmed Death 1 Ligand 1
24%
Retrospective Study
24%
Survival Rate
23%
Clinical Significance
23%
Lymph Node Metastasis
22%
Hazard Ratio
21%
Diseases
21%
Computer Assisted Tomography
20%
Surgical Anastomosis
20%
Biological Marker
19%
Recurrence Free Survival
18%
Multivariate Analysis
18%
Prognostic Factor
18%
Disease Free Survival
18%
Cancer
17%
Skeletal Muscle
17%
Retroperitoneal Lymph Node Dissection
17%
Adverse Event
16%
Progression Free Survival
16%
Bevacizumab
16%
Hepatectomy
16%
Total Stomach Resection
15%
Lung Cancer
15%
Sarcopenia
15%
Liver Transplantation
15%
Circulating Tumor DNA
14%
Laparoscopic Surgery
14%
Anastomosis Leakage
14%
Lymph Node
14%
Epidermal Growth Factor Receptor
14%
Breast Cancer
13%
Surgeon
13%
Nutritional Status
12%
Neoadjuvant Chemotherapy
12%
Primary Tumor
12%
Colorectal Liver Metastasis
12%
Microsatellite Instability
12%
Regorafenib
12%
Nutrition Assessment
12%
Metastatic Carcinoma
12%
Cancer Surgery
11%
Elderly Patient
11%
Esophagus
11%
Lymphocyte
11%
Inflammation
11%
Clinical Trial
11%
Capecitabine
10%
Phase II Trials
10%
Living Donors
10%
Fluorodeoxyglucose F 18
10%
Lung Metastasis
10%
Surgery
10%
Docetaxel
10%
Gastrointestinal Stromal Tumor
10%
Oral
10%
Cetuximab
9%
Prospective Study
9%
Cancer Cell
9%
Pneumonectomy
9%
Combination Therapy
9%
Arm
9%
Fluorouracil
9%
Trifluridine
9%
Tipiracil
9%
Radiation Therapy
8%
Cohort Analysis
8%
Carcinoma
8%
Telesurgery
8%
C Reactive Protein
8%
Positron Emission Tomography-Computed Tomography
8%
Neutropenia
8%
Clinical Stage
8%
Small Cell Lung Cancer
8%
Protein Expression
7%
Bleeding
7%
Immunohistochemistry
7%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
57%
Chemotherapy Regimens
52%
Oxaliplatin
45%
Abdominal Cancer
41%
Bevacizumab
38%
Irinotecan
32%
Colorectal Carcinoma
30%
Neoplasm
28%
Overall Survival
22%
Progression Free Survival
17%
Capecitabine
16%
Malignant Neoplasm
16%
Biological Marker
15%
Adverse Event
15%
Recurrent Disease
14%
Fluorouracil
13%
Colon Carcinoma
13%
Diseases
11%
Phase II Trials
11%
Survival Rate
11%
Trifluridine
10%
Fluoropyrimidine
10%
Breast Cancer
10%
Combination Therapy
10%
DNA Topoisomerase
9%
Tipiracil
8%
Clinical Trial
8%
Neutropenia
8%
Panitumumab
7%
Regorafenib
7%
Ramucirumab
7%
Anticarcinogen
7%
Placebo
6%
Circulating Tumor DNA
6%
Tipiracil Plus Trifluridine
6%
Prospective Study
6%
Cetuximab
6%
Colorectal Liver Metastasis
6%
Protein P53
5%
Esophageal Squamous Cell Carcinoma
5%
Vasculotropin
5%
Esophagus Cancer
5%
Disease Free Survival
5%
Carcinogenesis
5%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
23%
Overall Survival
23%
Cancer Cell
21%
P53
21%
Gene Mutation
17%
Genomics
17%
Carcinogenesis
16%
Messenger RNA
15%
Microsatellite Instability
15%
Chromosome Instability
14%
Colon
13%
Recurrence Free Survival
13%
Protein Expression
13%
Staining
11%
Tumor Progression
11%
Loss of Heterozygosity
10%
Topoisomerase
9%
DNA Topoisomerase
9%
Aneuploidy
9%
Cell Death
9%
Methylation
9%
Bevacizumab
9%
Expression Level
9%
Wild Type
9%
KRAS
8%
Genome Sequencing
8%
DNA Synthesis
8%
Cohort Study
7%
LGR5
7%
Transcription Factor EZH2
7%
Fluorouracil
7%
Prognostic Biomarker
7%
DNA Mismatch Repair
7%
Cytotoxicity
7%
Progression Free Survival
6%
Disease Free Survival
6%
Cancer Stem Cell
6%
Oncogene
6%
Quantitative Reverse Transcription Polymerase Chain Reaction
6%
Multivariate Analysis
6%
Computer Assisted Tomography
6%
Retrospective Study
6%
Gene Dosage
6%
Survival Rate
5%
Next Generation Sequencing
5%
Long Interspersed Repeat
5%
Cell Fate
5%
Binding Protein
5%
Circulating Tumor DNA
5%
Clinical Trial
5%
DNA Methylation
5%
Vimentin
5%
Kinase
5%
ARID1A
5%
Promoter Region
5%
Phosphotransferase
5%
Microsatellite
5%
phosphorylation
5%
Cadherin
5%